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Abstract 82 
 83 
 84 
Importance: Low-density lipoprotein (LDL) cholesterol-lowering alleles in or near NPC1L1 85 
or HMGCR, encoding the respective molecular targets of ezetimibe and statins, have 86 
previously been used as proxies to study the efficacy of these lipid-lowering drugs. Alleles 87 
near HMGCR are associated with a higher risk of type 2 diabetes, mimicking the increased 88 
incidence of new-onset diabetes associated with statin treatment in randomized clinical trials. 89 
It is unknown whether alleles near NPC1L1 are also associated with the risk of type 2 90 
diabetes.  91 
 92 
Objective: To investigate whether LDL-lowering alleles in or near NPC1L1 and other genes 93 
encoding current or prospective molecular targets of lipid-lowering therapy (i.e. HMGCR, 94 
PCSK9, ABCG5/G8, LDLR) are associated with the risk of type 2 diabetes.  95 
 96 
Design, Setting and Participants: The associations with type 2 diabetes and coronary artery 97 
disease of LDL-lowering genetic variants were investigated in meta-analyses of genetic 98 
association studies. Meta-analyses included 50,775 individuals with type 2 diabetes and 99 
270,269 controls including three studies and 60,801 individuals with coronary artery disease 100 
and 123,504 controls from a published meta-analysis. Data collection took place in Europe 101 
and the United States between 1991 and 2016.  102 
 103 
Exposure: LDL-lowering alleles in or near NPC1L1, HMGCR, PCSK9, ABCG5/G8, LDLR. 104 
 105 
Main Outcomes and Measures: Odds ratio of type 2 diabetes and coronary artery disease. 106 
 107 
Results: LDL-lowering genetic variants at NPC1L1 were inversely associated with coronary 108 
artery disease (odds ratio for a genetically-predicted reduction of 1 mmol/L in LDL 109 
cholesterol, 0.61; 95% confidence interval, 0.42-0.88; p=0.008) and directly associated with 110 
type 2 diabetes (2.42, 1.70-3.43; p<0.001). The odds ratio of type 2 diabetes for PCSK9 111 
genetic variants was 1.19 (95% confidence interval, 1.02-1.38, p=0.03). For a given reduction 112 
in LDL cholesterol, genetic variants were associated with a similar reduction in coronary 113 
artery disease risk (I-squared for heterogeneity in genetic associations=0.0%; p=0.93). 114 
However, associations with type 2 diabetes were heterogeneous (I-squared=77.2%; p=0.002), 115 
indicating gene-specific associations with metabolic risk for LDL-lowering alleles.  116 
 117 
Conclusions and Relevance: In this meta-analysis, exposure to LDL-cholesterol lowering 118 
genetic variants in or near NPC1L1 and other genes was associated with a higher risk of type 119 
2 diabetes. These data provide insights into potential adverse effects of LDL cholesterol-120 
lowering therapy.  121 
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Key Points 122 
 123 
• Question: Are LDL-cholesterol lowering alleles at NPC1L1 or other genes associated 124 
with the risk of type 2 diabetes? 125 
 126 
• Findings: In a meta-analysis of genetic association studies including 50,775 127 
individuals with type 2 diabetes and 270,269 controls, LDL-lowering polymorphisms at 128 
NPC1L1 were associated with a statistically significant odds ratio for type 2 diabetes of 2.42 129 
per genetically-predicted reduction of 1 mmol/L in LDL cholesterol. LDL-lowering 130 
polymorphisms at HMGCR and PCSK9 were also associated with a higher risk of diabetes. 131 
 132 
• Meaning: These data provide insights into potential adverse effects of LDL 133 
cholesterol-lowering therapy.  134 
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Introduction 135 
 Treatment with statins, the pharmacological agents of choice for low-density 136 
lipoprotein (LDL) cholesterol-lowering therapy in cardiovascular prevention,1,2 is associated 137 
with weight gain and a higher incidence of new-onset type 2 diabetes.3-5 Ezetimibe, an 138 
inhibitor of the LDL cholesterol transporter Niemann-Pick C1-like 1 (NPC1L1),6,7 has been 139 
approved as a lipid-lowering agent, but it is unclear whether its use will also be associated 140 
with an adverse metabolic risk profile.  141 
 There is considerable interest in predicting the efficacy and safety of therapeutic targets 142 
early in the drug development process. Drug targets with supporting human genetic evidence 143 
have been shown to have lower attrition rates during drug development,8 while variation in 144 
genes encoding drug targets has been used to predict both the efficacy and safety of 145 
pharmacological perturbation of those targets.9,10 In particular, LDL-lowering alleles in 146 
HMGCR5,11 encoding the molecular target of statins, have been successfully used as genetic 147 
proxies to study the effects of these drugs.5,11 Furthermore, LDL-lowering alleles at HMGCR 148 
are associated with higher risk of type 2 diabetes and higher body mass index in genetic 149 
studies,5 mimicking the safety profile of statins in meta-analyses of randomized clinical 150 
trials.3-5 151 
 The efficacy of adding ezetimibe to simvastatin in secondary cardiovascular prevention 152 
was supported by the IMPROVE-IT trial.6,7 Immediately before and after the publication of 153 
the trial results, studies were reported describing the use of genetic variants at NPC1L1 to 154 
predict the efficacy of NPC1L1 inhibition in the prevention of coronary events.11,12 The 155 
purpose of this study was to use naturally-occurring LDL-lowering alleles at NPC1L1 to 156 
investigate the potential associations between NPC1L1 inhibition and the risk of type 2 157 
diabetes. LDL-lowering alleles in or near genes encoding other current or prospective 158 
molecular targets of LDL-cholesterol lowering therapy were also studied. 159 
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Methods 160 
Study design 161 
 The association of LDL-cholesterol lowering polymorphisms near NPC1L1 with the 162 
risk of type 2 diabetes was investigated in meta-analyses of genetic association studies. In 163 
addition to NPC1L1 polymorphisms, the association of LDL-lowering alleles in or near genes 164 
encoding other current or prospective molecular targets of LDL-cholesterol lowering 165 
therapy11 (i.e. HMGCR, PCSK9, ABCG5/G8, LDLR) with type 2 diabetes, coronary artery 166 
disease and continuous cardiometabolic traits was also studied. A summary of the studies 167 
participating in each analysis is presented in eTable 1.  168 
 169 
Participants 170 
 The association of LDL-cholesterol lowering alleles with type 2 diabetes was estimated 171 
in a meta-analysis of 50,775 individuals with type 2 diabetes and 270,269 controls from the 172 
EPIC-InterAct study13, the UK Biobank study14 and the DIAbetes Genetics Replication And 173 
Meta-analysis (DIAGRAM).15 An additional eleven studies (4,496 cases and 50,677 controls) 174 
previously reported by Swerdlow and colleagues5 were included in analyses of the 175 
association with type 2 diabetes of rs12916 in HMGCR (eFigure 1). The combined 176 
association of NPC1L1 genetic variants in subgroups of age, sex, and body mass index was 177 
analyzed in 14,657 unrelated cases of type 2 diabetes and 118,854 controls from EPIC-178 
InterAct and UK Biobank with available individual-level genotyping data.  179 
 EPIC-InterAct is a case-cohort study nested within the European Prospective 180 
Investigation into Cancer and Nutrition (EPIC) study, a cohort study of 500,000 European 181 
participants followed-up for an average of 8 years.13 Eight of the ten constituent EPIC cohorts 182 
agreed to take part in EPIC-InterAct leaving 455,680 participants for screening. Individuals 183 
were excluded from EPIC-InterAct if they did not have stored blood (n=109,625) or 184 
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information on diabetes status (n=5,821; 1.3% of participants screened for inclusion). From 185 
the remaining 340,234 participants, 12,403 individuals who developed type 2 diabetes during 186 
follow-up constituted the incident case group of EPIC-InterAct and a random group of 16,154 187 
individuals free of diabetes at baseline constituted the subcohort group of EPIC-InterAct.13 188 
Subcohort participants were previously shown to be representative of eligible EPIC 189 
participants within each country.13 Data on a total of 20,831 participants with available 190 
genotyping (with no overlap with DIAGRAM15) were included in the main analysis, while 191 
data on all the 22,494 participants with available genotyping were included in subgroup 192 
analyses. Type 2 diabetes status was available in all participants. Individuals without 193 
genotype data were excluded from the study. Data collection took place between 1991 and 194 
2016. Participant characteristics and genotyping methods have been previously reported in 195 
detail13 and are summarized in Table 1 and eTable 2. 196 
 UK Biobank is a population-based cohort of 500,000 people aged between 40-69 years 197 
who were recruited in 2006-2010 from several centers across the United Kingdom.14 The 198 
association of genetic variants with prevalent type 2 diabetes was estimated in 6,627 cases 199 
and 143,765 controls of the UK Biobank dataset who had available genotype data. 200 
Genotyping was attempted in 152,770 individuals and failed in only 480 instances (0.3%). 201 
Among a total of 152,290 participants with available genotype data, type 2 diabetes status 202 
was adjudicated in 150,392 (98.8%) participants. Type 2 diabetes was defined on the basis of 203 
self-reported physician diagnosis at nurse interview or digital questionnaire, age at diagnosis 204 
> 36 years, and use of oral anti-diabetic medications. Data collection took place between 205 
2006 and 2016. Participant characteristics and genotyping information are reported in Table 206 
1 and eTable 2. 207 
 DIAGRAM is a research consortium that published the largest meta-analysis of 208 
genome-wide association studies for type 2 diabetes in individuals of European descent.15 209 
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Type 2 diabetes association results were made publicly available for up to 34,840 cases and 210 
114,981 controls from 38 genetic association studies with a case-control or cohort design.15  211 
Fifty percent of the participants were women and the average age was 55 years.15 Imputation 212 
was performed using the HapMap reference panel.15 Participant exclusion criteria 213 
encompassed duplicate samples, relatedness, mismatch between self-reported and genotype-214 
determined sex, outlying heterozygosity and non-European descent. Type 2 diabetes status 215 
was available in all participants. Data collection took place between 2002 and 2012. 216 
Participant characteristics are reported in Table 1 and further characteristics of studies 217 
included in the DIAGRAM meta-analysis were reported previously in detail.15 218 
 The likelihood of bias for studies participating in this meta-analysis was deemed low on 219 
the basis of: (a) the low proportion of participants with missing data on exposure or outcome, 220 
(b) the high-quality genotyping or imputation of genetic variants included in the study 221 
(eTable 2), (c) the low likelihood of bias by case-status in genotyping errors or genotype 222 
misclassification, (d) the consideration that if any non-differential misclassification of 223 
exposure or outcome occurred, that would result in a bias towards the null and (e) the 224 
consideration that genetic variants are less likely to be affected by confounding or reverse 225 
causality.16,17  On this basis, studies were deemed suitable for pooling by meta-analysis. 226 
 For the genetic variants included in these analyses, LDL cholesterol association 227 
estimates were obtained from genetic association results in up to 188,577 participants of the 228 
Global Lipids Genetics Consortium.18 In addition to type 2 diabetes, the association of these 229 
LDL-lowering alleles with coronary artery disease and continuous cardiometabolic traits was 230 
also estimated in large meta-analyses of genome-wide association studies. For coronary 231 
artery disease, data were from the CARDIoGRAMplusC4D Consortium meta-analysis 232 
(60,801 cases and 123,504 controls).19 For glycaemic traits, including fasting glucose20,21 233 
(N=133,010), glucose two hours after an oral glucose challenge20,22  (N=42,854) and fasting 234 
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insulin levels20,21 (natural-logarithm transformed; N=108,557), data were from the MAGIC 235 
Consortium.20-22 For anthropometric traits, including body mass index (N=333,495) and 236 
waist-to-hip ratio (N=224,047), data were from the GIANT consortium.23,24 For details, see 237 
eTable 1. 238 
 In exploratory analyses, the burden of protein-truncating and “probably deleterious” 239 
missense variants in NPC1L1, HMGCR, PCSK9, ABCG5, ABCG8 and LDLR was estimated 240 
from exome sequencing studies of 8,373 type 2 diabetes cases and 8,466 controls (AMP-T2D 241 
Program; T2D-GENES Consortium, SIGMA T2D Consortium. 2016 May 26; 242 
http://www.type2diabetesgenetics.org/). 243 
 244 
Selection of genetic variants  245 
  The combined association of two LDL cholesterol lowering genetic variants near 246 
NPC1L1 with type 2 diabetes constituted the primary analysis of the study (Table 2). These 247 
variants were identified as having distinct effects on LDL cholesterol levels in approximate 248 
conditional analyses using the GCTA software25,26 (see methodology description below; 249 
eFigure 2). In sensitivity analyses, the combined association of five LDL-lowering alleles 250 
near NPC1L1, previously used to predict the efficacy of ezetimibe,11 was also investigated 251 
(eTable 3). 252 
 For comparison with NPC1L1, other LDL-lowering alleles in or near genes encoding 253 
other current or prospective molecular targets of LDL-cholesterol lowering therapy (i.e. 254 
HMGCR, PCSK9, ABCG5/G8, LDLR) were studied.11 Three LDL-lowering polymorphisms 255 
in or near HMGCR, previously demonstrated to mimic the efficacy and metabolic effects of 256 
statins,5,11 were analyzed (Table 2). At the ABCG5/G8 and LDLR loci, polymorphisms 257 
previously used to investigate genetic relationships between LDL cholesterol and coronary 258 
artery disease11 were studied (Table 2). At the PCSK9 locus, in addition to the rs11591147 259 
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(p.R46L) variant (Table 2), the combined association of up to an additional eight likely-260 
independent LDL-lowering polymorphisms was investigated (eFigure 3). Genetic variants 261 
included in the analyses were strongly and specifically associated with LDL cholesterol 262 
(eFigure 4). 263 
 Approximate conditional analyses on large-scale LDL-cholesterol association data from 264 
the Global Lipids Genetics Consortium18 using the GCTA software25,26 were performed in 265 
order to identify distinct association signals for LDL cholesterol at the NPC1L1 and PCSK9 266 
loci. This approach uses genetic association results in addition to the linkage disequilibrium 267 
pattern in a reference population to estimate the association of genetic variants in a region 268 
after accounting for one or more index genetic variants. In so doing, the software allows for 269 
the identification of likely-independent association signals in a given region using result-level 270 
data. At the PCSK9 locus, in a smaller sample of individuals with individual-level genotypes, 271 
formal conditional analyses of the association with LDL cholesterol of polymorphisms after 272 
adjusting for rs11591147 genotype status were also conducted (eFigure 3).  273 
 274 
Genetic reference information 275 
 HUGO Gene Nomenclature Committee27 (URL: www.genenames.org) gene names for 276 
the investigated genes were: HGNC:7898 (NPC1L1), HGNC:5006 (HMGCR), HGNC:20001 277 
(PCSK9), HGNC:13886 (ABCG5), HGNC:13887 (ABCG8), HGNC:6547 (LDLR). Genomic 278 
coordinates reported in the manuscript represent the chromosome and physical position of 279 
genetic variants according to the Human Reference Genome Build 37 (URL: 280 
http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/). Polymorphism names reported 281 
in the manuscript represent rsID entries from dbSNP release 147 (URL: 282 
http://www.ncbi.nlm.nih.gov/SNP/). 283 
 284 
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Statistical analysis 285 
 Genetic association data for the meta-analyses were either generated or gathered from 286 
available sources at the MRC Epidemiology Unit, University of Cambridge (United 287 
Kingdom). For each genetic variant and outcome, inverse variance weighted meta-analyses 288 
using fixed-effect models was used to obtain pooled estimates. The I-squared statistic was 289 
used to quantify heterogeneity. For each gene, associations of LDL-lowering genetic variants 290 
and outcomes was estimated using Mendelian randomization statistical methodology.17 291 
Estimates of “genetic variant to LDL-cholesterol” and “genetic variant to outcome” 292 
associations were used to calculate estimates of “LDL-cholesterol reduction to outcome” 293 
association at each gene.17 When multiple genetic variants at a given gene were included in 294 
the model, estimates were pooled with a weighted generalized linear regression method that 295 
accounts for the correlation between genetic variants.17 The correlation values were obtained 296 
from the SNAP software28 or from the 1000 Genomes Project data on individuals of 297 
European ancestry (URL:http://browser.1000genomes.org/; eTable 4). Results were scaled to 298 
represent the odds ratio per 1 mmol/L genetically-predicted reduction in LDL cholesterol. 299 
Absolute risk differences were estimated assuming that the incidence rate of type 2 diabetes 300 
in the InterAct study subcohort would be the baseline incidence rate in “non-exposed” 301 
individuals (i.e. 3.76 incident cases per 1000 person-years of follow-up).13 This baseline rate 302 
was then multiplied by the odds ratio estimated from genetic analyses to obtain the “at risk” 303 
incidence rate. The absolute risk difference estimate was the “at risk” incidence rate minus 304 
the baseline incidence rate. Absolute risk differences were expressed in incident events per 305 
1000 person-years for a 1 mmol/L genetically-predicted reduction in LDL cholesterol. 306 
Statistical analyses were conducted using STATA v14.1 (StataCorp, College Station, Texas 307 
77845 USA), R v3.2.2 (The R Foundation for Statistical Computing), and METAL.29 A two-308 
tailed p-value of p<0.05 was considered statistically significant.  309 
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Results 310 
LDL cholesterol lowering alleles at NPC1L1 and risk of type 2 diabetes 311 
 LDL cholesterol lowering alleles at the NPC1L1 locus were inversely associated with 312 
coronary artery disease and directly associated with type 2 diabetes, both individually (Table 313 
2) and collectively (odds ratio of type 2 diabetes per 1 mmol/L genetically-predicted LDL 314 
cholesterol reduction, 2.42; 95% confidence interval, 1.70-3.43, p<0.001; estimated absolute 315 
risk difference, 5.3 incident cases per 1000 person-years for a 1 mmol/L genetically-predicted 316 
reduction in LDL cholesterol; Figure 1). For both polymorphisms, estimates of the 317 
association with type 2 diabetes were consistent across the studies included in the meta-318 
analysis (eFigure 1). In the periphery of the NPC1L1 locus, approximately 400 kilobases 319 
from the lead rs2073547 polymorphism, there was a known association signal for type 2 320 
diabetes and glycemic traits near the GCK gene.15,20,21 After accounting for variation in GCK, 321 
the association of with type 2 diabetes at NPC1L1 did not change (eTable 3). Association 322 
estimates also remained unchanged when modeling the association of five polymorphisms 323 
previously used by Ference et al.11 as a proxy for NPC1L1 inhibition (eTable 3). In 14,657 324 
cases of type 2 diabetes and 118,854 controls for whom we had access to individual-level 325 
genotyping data, there was no evidence of heterogeneity in the association between NPC1L1 326 
alleles and type 2 diabetes in analyses stratified by age, sex or body mass index (eFigure 5). 327 
In exome sequencing association results, there was no evidence of enrichment of NPC1L1 328 
protein truncating alleles in type 2 diabetes cases compared with controls (odds ratio of type 329 
2 diabetes for individuals carrying a truncating allele, 1.12; 95% confidence interval, 0.88-330 
1.43; p=0.34), but missense variants in NPC1L1 predicted to be “probably deleterious” were 331 
overrepresented in individuals with type 2 diabetes compared with controls (1.26, 1.07-1.47; 332 
p=0.005).   333 
 334 
 335 
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Associations with type 2 diabetes at other genes 336 
 As previously reported,5,11 LDL cholesterol lowering alleles at HMGCR were also 337 
associated with type 2 diabetes and coronary artery disease in opposite directions (Table 2 338 
and Figure 1). An association of the loss-of-function p.R46L (rs11591147) variant in PCSK9 339 
with higher risk of type 2 diabetes was also found (odds ratio of type 2 diabetes per 1 mmol/L 340 
genetically-predicted LDL cholesterol reduction, 1.19; 95% confidence interval, 1.02-1.38, 341 
p=0.03; estimated absolute risk difference, 0.7 incident cases per 1000 person-years for a 1 342 
mmol/L genetically-predicted reduction in LDL cholesterol; Table 2 and Figure 1). At 343 
PCSK9, analyses of the LDL cholesterol association data suggested the presence of distinct 344 
association signals. In formal conditional analyses, there was evidence of at least two distinct 345 
association signals (rs11591147 and rs471705; eFigure 3). Using the GCTA software,25,26 346 
approximate conditional analyses suggested the presence of nine distinct association signals 347 
(rs11591147 plus eight additional genetic variants; eFigure 3). Inclusion of these additional 348 
signals gave similar associations with type 2 diabetes as the p.R46L variant alone (odds ratio 349 
of type 2 diabetes per 1 mmol/L genetically-predicted reduction in LDL cholesterol using 350 
rs11591147 plus rs471705, 1.21, 95% confidence interval, 1.04-1.41, p=0.01; and 1.16, 1.03-351 
1.31, p=0.02, using rs11591147 plus the eight additional polymorphisms; eTable 3). The 352 
association with type 2 diabetes of LDL-lowering alleles at the ABCG5/G8 and LDLR loci 353 
did not reach statistical significance. There was no evidence of association with type 2 354 
diabetes for missense variants predicted to be “probably deleterious” or protein truncating 355 
alleles in the HMGCR, PCSK9, ABCG5, ABCG8 and LDLR genes (eTable 5), but the 356 
confidence intervals around risk estimates were generally wide, reflecting the low prevalence 357 
of these genetic variants and the relatively small sample size of this analysis.   358 
 359 
 360 
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Evidence of gene-specific associations with type 2 diabetes risk  361 
 In analyses of the association with disease risk for a given genetically-predicted 362 
reduction in LDL cholesterol, there was a similar reduction in coronary artery disease risk 363 
across genes (I-squared for heterogeneity in genetic associations = 0.0%; p=0.93, Figure 1). 364 
However, for the same reduction in LDL cholesterol, the association with type 2 diabetes risk 365 
differed by gene (I-squared = 77.2%; p=0.002, Figure 1). The different magnitudes and 366 
directions of association of LDL-lowering alleles with continuous glycemic and 367 
anthropometric traits suggested gene-specific mechanisms underlying the altered risk of type 368 
2 diabetes (eFigure 6). For example, at the HMGCR locus there were associations with body 369 
mass index and waist-to-hip ratio, while at the PCSK9 locus there were associations with 370 
higher fasting glucose and two hour glucose (eFigure 6).   371 
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Discussion 372 
 In this meta-analysis, exposure to LDL-cholesterol lowering genetic variants in or near 373 
the NPC1L1 gene was associated with a higher risk of type 2 diabetes. This finding is 374 
consistent with the results of a small-scale open label randomized clinical trial, showing 375 
increased glycated hemoglobin in association with ezetimibe treatment.30 Blazing et al. 376 
reported that the addition of ezetimibe to simvastatin for secondary cardiovascular prevention 377 
in the IMPROVE-IT trial resulted in a small and not statistically significant increase in risk of 378 
new-onset diabetes (9% relative risk increase per 1 mmol/L reduction in LDL cholesterol).31 379 
However, IMPROVE-IT results may not be sufficient to rule out an effect of inhibiting 380 
Niemann-Pick C1-like 1 on diabetes risk because: (1) some of the effects of NPC1L1 381 
inhibition may be apparent only after several years of treatment; (2) the risk of type 2 382 
diabetes in individuals with a history of acute coronary syndrome yet free from type 2 383 
diabetes in IMPROVE-IT may not reflect that of the general population on which this genetic 384 
analysis is based; (3) limited compliance to drug treatment, as observed in IMPROVE-IT,7 385 
may dilute etiologic effect estimates. By analogy, the association of statin treatment with 386 
higher diabetes risk was only demonstrable in a meta-analysis of several randomized clinical 387 
trials including more than 90,000 individuals.3 Therefore, these results warrant the continued 388 
monitoring of the glycemic effects of ezetimibe in randomized clinical trials and clinical 389 
practice particularly in a primary prevention setting.  390 
The results of this study show that multiple LDL-lowering mechanisms, including those 391 
mediated by the molecular targets of available LDL-lowering drugs (i.e. statins, ezetimibe, 392 
and PCSK9 inhibitors), are associated with adverse metabolic consequences and increased 393 
type 2 diabetes risk. These findings are consistent with other studies of the association with 394 
type 2 diabetes of genetic scores aggregating multiple polymorphisms affecting LDL 395 
cholesterol and other lipid fractions.32 They are also consistent with the observation that 396 
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patients with familial hypercholesterolemia are less likely to have type 2 diabetes.33 The 397 
genes which were associated both with lower LDL cholesterol levels and higher type 2 398 
diabetes risk impact on LDL cholesterol by distinct pathways including cholesterol 399 
absorption (NPC1L1),34 endogenous cholesterol synthesis (HMGCR)35 and internalization of 400 
cholesterol-rich particles into the cell (PCSK9).36,37 For a similar reduction in LDL 401 
cholesterol, the association with type 2 diabetes differed by gene which would be consistent 402 
with the mediation of their associations by different mechanisms. Besseling et al. have 403 
proposed that an increased internalization of cholesterol into pancreatic beta-cells may result 404 
in impaired secretion of insulin,33 a hypothesis supported by murine experimental models.38 405 
LDL cholesterol lowering alleles at HMGCR are associated with higher fasting insulin and 406 
body mass index, suggesting an insulin resistance-related mechanism.5 Finally, in contrast 407 
with early evidence showing metabolic benefits of NPC1L1 knock-out in mice,39 recent 408 
studies suggest that its over expression in the liver may suppress gluconeogenesis and, 409 
therefore, that its inhibition could perhaps enhance glucose production.40 Overall, these 410 
results indicate complex relationships between the mechanisms leading to lower LDL 411 
cholesterol and metabolic risk. 412 
Contrary to previous, smaller-scale investigations,41 there were associations of the 413 
p.R46L variant in PCSK9 (rs11591147) with a higher risk of type 2 diabetes, and higher 414 
fasting and two hour glucose. These associations have to be interpreted with caution, given 415 
the level of statistical significance for the association and the context of multiple comparisons 416 
presented in this study. This finding nonetheless suggests that the effect of LDL-lowering 417 
drugs on increased diabetes risk might extend to the newly-developed PCSK9 inhibitors, 418 
encouraging further genetic and clinical trial investigations.  419 
In general, unlike the association of LDL-lowering alleles with cardiovascular risk, the 420 
association of these alleles with metabolic risk appears to be gene-specific, which in turn 421 
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might suggest that the adverse consequences of lipid-lowering agents on diabetes risk could 422 
be target-specific. This may have clinical implications for the future of lipid-lowering therapy 423 
in the context of the growing number of approved drugs acting on different molecular targets. 424 
The overall safety profile of these drugs, including the magnitude of risk of new-onset type 2 425 
diabetes, may be relevant to the choice of specific agent for subsets of the patient population, 426 
for example those at high risk of type 2 diabetes who are also candidates for lipid-lowering 427 
therapy.  428 
 A number of assumptions and potential limitations of the genetic approach used in this 429 
study should be considered. “Mendelian randomization” generally assumes that genetic 430 
variants are associated with the endpoint exclusively via the risk factor of interest.16,17 The 431 
strong and specific association with LDL cholesterol, the well-known role of target genes in 432 
LDL cholesterol metabolism and the use of conditionally-distinct genetic variants at given 433 
loci strengthen the validity of the genetic models used in this study. Similar to previous 434 
examples,5,11,42 the aim of this study was to use genetic variants that “mimic” the action of 435 
pharmacological therapy and therefore “pleiotropy” (i.e. the association with variables other 436 
than LDL cholesterol) may be more informative than concerning. For instance, HMGCR 437 
genetic variants are associated with higher body mass index, consistent with the effects on 438 
body weight observed in randomized clinical trials of statins.5 However, the consequences of 439 
modest reductions in LDL cholesterol associated with LDL-lowering alleles over several 440 
decades, as assessed in this study, may differ from the short-term pharmacological inhibition 441 
of a molecular target in randomized clinical trials or clinical practice. Finally, several of the 442 
included studies were population-based and therefore association estimates from these studies 443 
may not be applicable to patient groups in whom a particular therapy is indicated. 444 
 445 
 446 
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Conclusions 447 
In this meta-analysis, exposure to LDL-cholesterol lowering genetic variants in or 448 
near NPC1L1 and other genes was associated with a higher risk of type 2 diabetes. These data 449 
provide insights into potential adverse effects of LDL cholesterol-lowering therapy. 450 
  451 
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Table 1. Participants of EPIC-InterAct, UK Biobank and DIAGRAM.  452 
 453 
Variable 
EPIC-InterAct UK Biobank DIAGRAM 
Type 2 
diabetes 
Subcohort 
(non-cases) 
Type 2 
diabetes Controls 
Type 2 
diabetes Controls 
Country Multiple European countries United Kingdom Europe and United States
c 
Genotyping chip 
Illumina 660w quad and 
Illumina CoreExome 
chip 
Affymetrix UK Biobank 
Axiom Array Multiple
d 
Imputation panel Haplotype Reference Consortium 
1000 Genomes Phase 3 
plus UK10K HapMap 
Number 10,071a 12,423a 6,627 143,765 34,840 114,981 
Age, mean years 
(SD) 56 (8) 52 (9) 60 (7) 56 (8) 59 (10) 54 (14) 
Female sex, N (%) 5,037 (50) 7,713 (62) 2,349 (35) 77,397 (54) 14,621 (42) 60,377 (53) 
Smoking status, 
current smokers N 
(%) 
2,830 (28) 3,240 (26) 811 (12) 18,149 (13) NA NA 
BMI in kg/m2, 
mean (SD) 29.7 (4.8) 25.8 (4.1) 31.9 (5.9) 27.3 (4.7) 29.7 (5.9) 26.5 (4.5) 
Waist-to-hip ratio 0.92 (0.09) 0.85 (0.09) 0.95 (0.08) 0.87 (0.09) NA NA 
Systolic blood 
pressure in mmHg, 
mean (SD) 
144 (20) 132 (19) 141 (17) 138 (19) NA NA 
Diastolic blood 
pressure in mmHg, 
mean (SD) 
87 (11) 82 (11) 82 (10) 82 (10) NA NA 
LDL cholesterol in 
mmol/L, mean (SD) 4.0 (1) 3.8 (1) NA
b NAb NA NA 
HDL cholesterol in 
mmol/L, mean (SD) 1.2 (0.4) 1.5 (0.4) NA
b NAb NA NA 
Triglycerides in 
mmol/L, median 
(IQR) 
1.7  
(1.2-2.5) 
1.1  
(0.8-1.6) NA
b NAb NA NA 
Abbreviations: N, number of participants; BMI, body mass index; SD, standard deviation; LDL, low-density lipoprotein 454 
cholesterol; HDL, high-density lipoprotein cholesterol; IQR, interquartile range; NA, not available.  455 
a A total of 9,308 type 2 diabetes cases and 11,523 non-cases were included in the main analysis of the association of genetic 456 
variants with type 2 diabetes after the exclusion of participants overlapping with DIAGRAM. 457 
b Blood lipids concentrations are being measured in the UK Biobank study, with data release currently planned for the end 458 
of 2016. 459 
c DIAGRAM had a small South Asian component accounting for 2.44% of participants. 460 
d Affymetrix Human SNP Array 6.0; Illumina HumanHap 300, 300/370 and 550; Affymetrix Genechip 500K & MIPS 50K; 461 
Cardio-Metabolchip.  462 
 463 
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Table 2. LDL-cholesterol lowering polymorphisms at NPC1L1 and other genes and their association with type 2 diabetes and coronary 464 
artery disease.  465 
 466 
Gene dbSNP rsID 
Genomic 
coordinate, 
chromosome 
and position 
Effect / 
other 
allele 
Effect 
allele 
frequency, 
mean 
(range) 
LDL, N 
Beta  
(95% CI)  
per allele in 
mmol/La 
p-value 
OR of 
coronary 
artery disease 
(95% CI) 
per alleleb 
p-value 
OR of type 2 
diabetes 
(95% CI) 
per allelec 
p-value I-squared Heterogeneity p-value 
NPC1L1 
rs2073547 chr7:44582331 A / G 0.81 (0.81, 0.82) 169,889 
-0.049  
(-0.058, -0.039) 2 x 10
-21 0.980 (0.957, 1.003) 0.09 
1.051 
(1.027, 1.075) 2 x 10
-05 0.0% 0.48 
rs217386 chr7:44600695 A / G 0.42 (0.41, 0.44) 173,021 
-0.036 
(-0.044, -0.029) 1 x 10
-19 0.979 (0.960, 0.998) 0.03 
1.027 
(1.009, 1.045) 0.003 0.0% 0.68 
HMGCR 
rs12916 d chr5:74656539 T / C 0.58 (0.57, 0.60) 168,357 
-0.073 
(-0.081, -0.066) 8 x 10
-78 0.965 (0.947, 0.983) 0.0002 
1.029 
(1.012, 1.046) 0.0007 46.4% 0.03 
rs5744707 chr5:74890618 A / G 0.90 (0.90, 0.91) 172,928 
-0.055 
(-0.067, -0.043) 6 x 10
-19 0.970 (0.941, 0.999) 0.04 
0.983 
(0.956, 1.011) 0.24 2.8% 0.38 
rs16872526 chr5:74675717 T / G 0.91 (0.90, 0.92) 173,009 
-0.041 
(-0.054, -0.027) 2 x 10
-08 0.988 (0.959, 1.018) 0.44 
1.016 
(0.985, 1.047) 0.32 50.1% 0.11 
PCSK9 rs11591147 chr1:55505647 T / G 0.02 (0.01, 0.02) 77,417 
-0.497 
(-0.532, -0.462) 9 x 10
-143 0.774 (0.692, 0.866) 7 x 10
-06 1.089 (1.010, 1.174) 0.03 0.0% 0.39 
ABCG5/G8 rs4299376 chr2:44072576 T / G 0.69 (0.68, 0.70) 144,861 
-0.081 
(-0.090, -0.072) 4 x 10
-72 0.950 (0.931, 0.970) 1 x 10
-06 1.011 (0.990, 1.032) 0.29 2.2% 0.38 
LDLR rs6511720 chr19:11202306 T / G 0.11 (0.10, 0.12) 170,608 
-0.221 
(-0.233, -0.209) 4 x 10
-262 0.882 (0.853, 0.912) 1 x 10
-13 1.028 (0.999, 1.057) 0.05 0.0% 0.93 
Polymorphism names reported in the table are rsID entries from dbSNP release 147. 467 
Genomic coordinates represent chromosome and physical position of genetic variants according to the Human Reference Genome Build 37.  468 
Effect allele frequency averages and ranges are from EPIC-InterAct,13 UK Biobank14 and DIAGRAM.15 469 
Abbreviations: LDL, low-density lipoprotein cholesterol;  N, number of participants; CI, confidence interval; CAD, coronary artery disease; T2D, type 2 diabetes; OR, odds 470 
ratio. 471 
a LDL cholesterol data were from the Global Lipids Genetics Consortium.18 472 
b Coronary artery disease data were from 60,801 coronary artery disease cases and 123,504 controls from the CARDIoGRAMplusC4D Consortium.19 473 
c Type 2 diabetes data were from 50,775 cases of type 2 diabetes and 270,269 controls from EPIC-InterAct,13 UK Biobank14 and DIAGRAM.15 474 
d In addition to EPIC-InterAct,13 UK Biobank14 and DIAGRAM.15, type 2 diabetes association analyses of rs12916 included eleven studies (4,496 cases and 50,677 controls) 475 
previously reported by Swerdlow and colleagues.5 The total sample size of this analysis was of 55,271 cases of type 2 diabetes and 320,946 controls.  476 
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Figure Legend  477 
Figure 1 Title. Odds ratio of coronary artery disease and type 2 diabetes associated with 478 
LDL-lowering genetic variants in or near investigated genes.  479 
 480 
Figure 1 Footnote: Coronary artery disease data were from 60,801 coronary artery disease cases and 123,504 481 
controls from the CARDIoGRAMplusC4D Consortium.19 Type 2 diabetes data were from 50,775 cases of type 482 
2 diabetes and 270,269 controls from EPIC-InterAct,13 UK Biobank14 and DIAGRAM.15 In addition to EPIC-483 
InterAct,13 UK Biobank14 and DIAGRAM.15, type 2 diabetes association analyses of rs12916 at HMGCR 484 
included eleven studies (4,496 cases and 50,677 controls) previously reported by Swerdlow and colleagues.5 485 
Therefore the sample size of HMGCR genetic variants association with type 2 diabetes was of up to 55,271 486 
cases of type 2 diabetes and 320,946 controls. All results are scaled to represent the odds ratio per 1 mmol/L 487 
genetically-predicted reduction in LDL cholesterol. Abbreviations: SNP, single nucleotide polymorphism; OR, 488 
odds ratio; CAD, coronary artery disease; T2D, type 2 diabetes; LDL, low-density lipoprotein cholesterol.489 
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